Janus Henderson Group
ACRS icon

Janus Henderson Group’s Aclaris Therapeutics ACRS Stock Holding History

Janus Henderson Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,799,759
Closed -$6.99M – 2482
2024
Q4 		$6.99M Buy
+2,799,759
New +$6.97M ﹤0.01% 807
2024
Q1 		– Sell
-20,300
Closed -$21.4K – 2528
2023
Q4 		$21.4K Sell
20,300
-53
-0.3% -$162 ﹤0.01% 2544
2023
Q3 		$140K Buy
20,353
+30
+0.1% +$256 ﹤0.01% 2459
2023
Q2 		$211K Sell
20,323
-66
-0.3% -$597 ﹤0.01% 2426
2023
Q1 		$165K Buy
+20,389
New +$259K ﹤0.01% 2541

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group's ACRS Position: Q1 2025 in Review

Janus Henderson Group sold out of Aclaris Therapeutics (ACRS) in Q1 2025, closing a stake of 2,799,759 shares — an estimated $6.99M sold.

Janus Henderson Group first reported a position in ACRS in Q1 2023 and held it in 5 quarters. The position peaked at $6.99M in Q4 2024. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2025.

  • Janus Henderson Group reported no remaining Aclaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Janus Henderson Group sold 2,799,759 Aclaris Therapeutics shares in Q1 2025, an estimated $6.99M.
  • Janus Henderson Group first reported a position in Aclaris Therapeutics in Q1 2023 and held it in 5 quarters.
  • Janus Henderson Group's Aclaris Therapeutics position peaked at $6.99M in Q4 2024.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2025.

Based on Janus Henderson Group's 13F filing for Q1 2025, filed 15 May 2025.